Cisplatin and protracted venous infusion 5-fluorouracil (CF) - good symptom relief with low toxicity in advanced pancreatic carcinoma
Authors: Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'brien, M., Hill, A. and Hickish, T.
Journal: Annals of Oncology
Volume: 6
Issue: 8
Pages: 801-804
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a059319
Abstract:Purpose: The combination of protracted venous infusion (PVI) 5-FU with moderate dose cisplatin was evaluated in patients with advanced pancreatic cancerPatients and methods: Sixty-three patients with locally advanced or metastatic disease were treated with cisplatin (60 mg/m2 every 21 days) and PVI 5-FU (300 mg/m2/day) for a maximum of 24 weeks. All patients had histologkally/ cytologically confirmed tumour. Radiological response was assessed by CT scanning and toxicity, performance status and symptomatic response were assessed 3 weeklyResults: The objective response rate was 16% with two radiological complete responses. The median survival was 7.6 months with a 1-year survival of 33% and a median progression-free survival of 6.6 months. Patients who had local disease only had a median survival of 14.8 months with a 1-year survival of 52%. Thirty-four percent of patients had an improvement in performance status on treatment and specific symptom response rates were weight loss 71%, dysphagia 100%, nausea and vomiting 70%, pain 60%, anorexia 50% and reflux 81%. Chemotherapy was well tolerated with grade 3 or 4 toxicity being nausea/vomiting 5%, diarrhoea 7%, infection 4%, stomatitis 2%, plantar palmar syndrome 2%, anaemia 14%, leucopenia 5%, neutro-penia 10% and thrombocytopenia 8%Conclusions: The CF regimen provides good symptomatic palliation with low toxicity in patients with advanced pancreatic cancer © 1995 Kluwer Academic Publishers.
Source: Scopus
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Authors: Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A. and Hickish, T.
Journal: Ann Oncol
Volume: 6
Issue: 8
Pages: 801-804
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a059319
Abstract:PURPOSE: The combination of protracted venous infusion (PVI) 5-FU with moderate dose cisplatin was evaluated in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Sixty-three patients with locally advanced or metastatic disease were treated with cisplatin (60 mg/m2 every 21 days) and PVI 5-FU (300 mg/m2/day) for a maximum of 24 weeks. All patients had histologically/cytologically confirmed tumour. Radiological response was assessed by CT scanning and toxicity, performance status and symptomatic response were assessed 3 weekly. RESULTS: The objective response rate was 16% with two radiological complete responses. The median survival was 7.6 months with a 1-year survival of 33% and a median progression-free survival of 6.6 months. Patients who had local disease only had a median survival of 14.8 months with a 1-year survival of 52%. Thirty-four percent of patients had an improvement in performance status on treatment and specific symptom response rates were weight loss 71%, dysphagia 100%, nausea and vomiting 70%, pain 60%, anorexia 50%, and reflux 81%. Chemotherapy was well tolerated with grade 3 or 4 toxicity being nausea/vomiting 5%, diarrhoea 7%, infection 4%, stomatitis 2%, plantar palmar syndrome 2%, anaemia 14%, leucopenia 5, neutropenia 10% and thrombocytopenia 8%. CONCLUSIONS: The CF regimen provides good symptomatic palliation with low toxicity in patients with advanced pancreatic cancer.
Source: PubMed
Preferred by: Tamas Hickish
Cisplatin and protracted venous infusion 5-fluorouracil (CIF) - good symptom relief with low toxicity in advanced pancreatic carcinoma
Authors: Nicolson, M., Webb, A., Cunningham, D., Norman, A., OBrien, M., Hill, A. and Hickish, T.
Journal: ANNALS OF ONCOLOGY
Volume: 6
Issue: 8
Pages: 801-804
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a059319
Source: Web of Science (Lite)
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Authors: Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A. and Hickish, T.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Volume: 6
Issue: 8
Pages: 801-804
eISSN: 1569-8041
ISSN: 0923-7534
DOI: 10.1093/oxfordjournals.annonc.a059319
Abstract:Purpose
The combination of protracted venous infusion (PVI) 5-FU with moderate dose cisplatin was evaluated in patients with advanced pancreatic cancer.Patients and methods
Sixty-three patients with locally advanced or metastatic disease were treated with cisplatin (60 mg/m2 every 21 days) and PVI 5-FU (300 mg/m2/day) for a maximum of 24 weeks. All patients had histologically/cytologically confirmed tumour. Radiological response was assessed by CT scanning and toxicity, performance status and symptomatic response were assessed 3 weekly.Results
The objective response rate was 16% with two radiological complete responses. The median survival was 7.6 months with a 1-year survival of 33% and a median progression-free survival of 6.6 months. Patients who had local disease only had a median survival of 14.8 months with a 1-year survival of 52%. Thirty-four percent of patients had an improvement in performance status on treatment and specific symptom response rates were weight loss 71%, dysphagia 100%, nausea and vomiting 70%, pain 60%, anorexia 50%, and reflux 81%. Chemotherapy was well tolerated with grade 3 or 4 toxicity being nausea/vomiting 5%, diarrhoea 7%, infection 4%, stomatitis 2%, plantar palmar syndrome 2%, anaemia 14%, leucopenia 5, neutropenia 10% and thrombocytopenia 8%.Conclusions
The CF regimen provides good symptomatic palliation with low toxicity in patients with advanced pancreatic cancer.Source: Europe PubMed Central